|
101 |
Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies
Enthalten in Cell discovery Bd. 8, 7.10.2022, Nr. 1, date:12.2022: 1-15
|
|
|
|
102 |
Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute myeloid leukemia: a preclinical assessment
Enthalten in Leukemia Bd. 38, 11.1.2024, Nr. 2, date:2.2024: 398-402
|
|
|
|
103 |
Construction of bispecific antibodies by specific pairing between the heavy chain and the light chain using removable SpyCatcher/SnoopCatcher units
Enthalten in Journal of biological engineering Bd. 18, 14.10.2024, Nr. 1, date:12.2024: 1-7
|
|
|
|
104 |
Construction of Novel Bispecific Single-Domain Antibodies (BiSdAbs) with Potent Antiangiogenic Activities
Enthalten in Pharmaceutical fronts Bd. 02, 2020, Nr. 01: e64-e76
|
|
|
|
105 |
Correction to: Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting
Enthalten in Experimental hematology & oncology Bd. 12, 3.10.2023, Nr. 1, date:12.2023: 1-4
|
|
|
|
106 |
COVID-19 infection outcomes in patients receiving CD20 targeting T-cell engaging bispecific antibodies for B-cell non-Hodgkin lymphoma
Enthalten in Annals of hematology Bd. 102, 9.6.2023, Nr. 9, date:9.2023: 2635-2637
|
|
|
|
107 |
Design of Crosslinking Antibodies For T-Cell Activation: Experimental and Computational Analysis of PD-1/CD137 Bispecific Agents
Enthalten in American Association of Pharmaceutical Scientists: The AAPS journal Bd. 26, 11.6.2024, Nr. 4, date:8.2024: 1-13
|
|
|
|
108 |
Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment
Enthalten in Experimental hematology & oncology Bd. 6, 28.11.2017, Nr. 1, date:12.2017: 1-15
|
|
|
|
109 |
Development of a bioassay to detect T-cell-activating impurities for T-cell-dependent bispecific antibodies
Enthalten in Scientific reports Bd. 9, 7.3.2019, Nr. 1, date:12.2019: 1-9
|
|
|
|
110 |
Directing HIV-1 for degradation by non-target cells, using bi-specific single-chain llama antibodies
Enthalten in Scientific reports Bd. 12, 4.8.2022, Nr. 1, date:12.2022: 1-14
|
|
Administration
